The treatment of chronic myeloid leukemia (CML) has been advanced by the development of small-molecule tyrosine kinase inhibitors (TKIs), which target the fusion protein BCR-ABL1 expressed by the Philadelphia chromosome. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.